Clinical Trials

23 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT06561360 2026-05-26

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Other hematologic neoplasm

86 enrolled

Leukemia, Hairy Cell

NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06943872 2026-05-26

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

155 enrolled

Phase 1 Active not recruiting

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04277637 2026-05-22

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

437 enrolled

Mature B-Cell Malignancies

NCT04269902 2026-05-19

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

247 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05057494 2026-05-19

MAJIC

607 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06849713 2026-05-19

BOSon

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07003295 2026-05-19

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

Lymphoma, Mantle-Cell

NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

121 enrolled

Lymphoma, Non-Hodgkin

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4 Recruiting

60 enrolled

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06867536 2026-05-15

GLOHRT-01

40 enrolled

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03269669 2026-05-13

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Lymphoma, Follicular

NCT03701282 2026-05-13

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

42 enrolled 10 charts

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT06504199 2026-05-13

ZGR

39 enrolled

Lymphoma, Mantle-Cell

NCT06649812 2026-05-13

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

120 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07261163 2026-05-13

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

37 enrolled

Lymphoma, Mantle-Cell

NCT07299149 2026-05-13

ZGR in TN FL

34 enrolled

Lymphoma, Follicular

NCT06073821 2026-05-11

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

652 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT03462719 2026-05-08

GLOW

211 enrolled 23 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03824483 2026-05-07

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

230 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03322865 2026-05-06

Obinutuzumab in Marginal Zone Lymphoma

56 enrolled

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT05896163 2026-05-06

MAPtivate-6

Phase 1/2 Terminated

40 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-05-06

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT05848765 2026-05-05

REFRACT

284 enrolled

Lymphoma, Lymphoma, Follicular

NCT05533775 2026-05-04

iMATRIX GLO

Phase 1/2 Recruiting

65 enrolled

Recurrence

NCT06084936 2026-05-04

GLOBRYTE

182 enrolled

Lymphoma

NCT06624085 2026-05-04

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

50 enrolled